Elshot Yannick S, Zupan-Kajcovski Biljana, Ouwerkerk Wouter, Klop W Martin C, Lohuis Peter J F M, Bol Mijke, Crijns Marianne B, Bekkenk Marcel W, de Rie Menno A, Balm Alfons J M
Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Postbus 90203, 1006 BE, Amsterdam, the Netherlands; Department of Dermatology, Amsterdam UMC, Univ. of Amsterdam, Postbus 22660, 1100 DD, Amsterdam, the Netherlands.
Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Postbus 90203, 1006 BE, Amsterdam, the Netherlands.
Eur J Surg Oncol. 2023 Apr;49(4):818-824. doi: 10.1016/j.ejso.2022.08.012. Epub 2022 Aug 18.
Knowledge about lentigo maligna (melanoma) (LM/LMM) and its associated prognostic clinicopathological characteristics are limited compared to that of non-LM/LMM subtypes. The current study aimed to determine the clinical relevance of the LM/LMM subtype and its influence on recurrence and survival outcomes.
All consecutive cases of primary cutaneous head and neck LM/LMM treated by wide local excision over a ten-year period were retrospectively reviewed and compared to non-LM/LMM. Clinical outcome and prognostic factors were assessed by cumulative incidence and competing risk analyses.
A total of 345 patients were identified. Specific clinicopathological characteristics such as lower median Breslow thickness (1.6 mm versus 2.1 mm; P = 0.013), association with diagnostic sampling errors (17.3% versus 5.2%; P = 0.01), and increased risk of local recurrences due to incomplete resection (18.7% versus 2.3%; P < 0.001), were significantly associated with LM/LMM. Guideline adherence was similar between the two study groups. The positive nodal status at baseline for LMM was low compared to non-LM/LMM (4.2% vs 17.9%; P = 0.037). The LMM subtype, facial localization, and reduced surgical margins (i.e., guideline non-adherence) were not shown to be independent prognostic factors for disease-free, melanoma-specific, or overall survival after correction for competing risks such as patient age and Breslow thickness.
The LMM subtype was not shown to be prognostically different from non-LM/LMM when corrected for other variables of influence such as patient age and Breslow thickness. Reduced resection margins did not seem to affect disease-free, and melanoma-specific survival and warrant LM/LMM-specific guidelines. Further research is needed to evaluate the value of SLNB in LMM patients.
与非恶性雀斑样痣黑色素瘤(LM/LMM)亚型相比,关于恶性雀斑样痣(黑色素瘤)(LM/LMM)及其相关预后临床病理特征的知识有限。本研究旨在确定LM/LMM亚型的临床相关性及其对复发和生存结果的影响。
回顾性分析了10年间所有经广泛局部切除治疗的原发性头颈部皮肤LM/LMM连续病例,并与非LM/LMM病例进行比较。通过累积发病率和竞争风险分析评估临床结局和预后因素。
共纳入345例患者。特定的临床病理特征,如较低的中位Breslow厚度(1.6mm对2.1mm;P = 0.01)、与诊断性采样误差相关(17.3%对5.2%;P = 0.01)以及因切除不完全导致局部复发风险增加(18.7%对2.3%;P < 0.001),均与LM/LMM显著相关。两个研究组在遵循指南方面相似。与非LM/LMM相比,LMM基线时阳性淋巴结状态较低(4.2%对17.9%;P = 0.037)。在校正患者年龄和Breslow厚度等竞争风险后,LMM亚型、面部定位和手术切缘缩小(即未遵循指南)未被证明是无病生存期、黑色素瘤特异性生存期或总生存期的独立预后因素。
在校正患者年龄和Breslow厚度等其他影响变量后,LMM亚型在预后方面与非LM/LMM无差异。手术切缘缩小似乎不影响无病生存期和黑色素瘤特异性生存期,因此需要LM/LMM特异性指南。需要进一步研究评估前哨淋巴结活检在LMM患者中的价值。